A Question For Parallel Review Planners: When CMS Should Get Involved
This article was originally published in The Gray Sheet
Executive Summary
As FDA and CMS officials develop steps for parallel medical product reviews, a key question is when CMS should be brought into the pre-market process.
You may also be interested in...
Parallel Reviews Should Lead To Local Coverage, Coding Decisions, Firms Say
Device makers say that for FDA and CMS parallel reviews to be successful, they must enable local coverage determinations and coding decisions, not just national coverage decisions.
Parallel Reviews Should Lead To Local Coverage, Coding Decisions, Firms Say
Device makers say that for FDA and CMS parallel reviews to be successful, they must enable local coverage determinations and coding decisions, not just national coverage decisions.
Device Firms Weigh Pros And Cons Of FDA-CMS Parallel Review
As FDA and CMS edge closer to a joint program for pre-market review and reimbursement decision-making, device and diagnostic firms are expressing wariness about participating.